Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2018

Open Access 01-12-2018 | Research

The detection of 3 ambiguous type 2 vaccine-derived polioviruses (VDPV2s) in Uganda

Authors: Mary Bridget Nanteza, Barnabas Bakamutumaho, Annet Kisakye, Prossy Namuwulya, Henry Bukenya, Edson Katushabe, Josephine Bwogi, Charles Rutebarika Byabamazima, Raffaella Williams, Nicksy Gumede

Published in: Virology Journal | Issue 1/2018

Login to get access

Abstract

Background

The Oral Polio Vaccine (OPV or Sabin) is genetically unstable and may mutate to form vaccine-derived polioviruses (VDPVs).

Methods

In 2014, two VDPVs type 2 were identified during routine surveillance of acute flaccid paralysis (AFP) cases. Consequently, a retrospective VDPV survey was conducted to ensure that there was no circulating VDPV in the country. All Sabin poliovirus isolates identified in Uganda 6 months before and 6 months after were re-screened; Sabin 1 and 3 polioviruses were re-screened for Sabin 2 and Sabin 2 polioviruses were re-screened for VDPVs type 2. The Poliovirus rRT-PCR ITD/VDPV 4.0 assay and sequencing were used respectively.

Results

The first two VDPVs type2 were identified in Eastern Uganda and the third was identified during the survey from South-western Uganda. These regions had low OPV coverage and poor AFP surveillance indicators.

Conclusion

The retrospective VDPV survey was a useful strategy to screen for VDPVs more exhaustively. Supplementary surveillance methods need to be encouraged.
Appendix
Available only for authorised users
Literature
1.
EA C. Spread of vaccine-derived poliovirus from a paralytic case in an Immunodeficient child: an insight into the natural evolution of oral polio vaccine. Virology. 2005;
2.
3.
Wassilak S, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis. 2011;203(7):898–909.CrossRefPubMedPubMedCentral
4.
World Health Organization. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2003-June 2004. Wkly Epidemiol Rec. 2004;79:393–399.
5.
Sharif S, et al. Evolution and circulation of type-2 vaccine-derived polioviruses in Nad Ali district of southern Afghanistan during June 2009-February 2011. PLoS One. 2014;9(2):e88442.CrossRefPubMedPubMedCentral
6.
7.
Kew OM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587–635.CrossRefPubMed
8.
Alexander JP Jr, Gary HE Jr, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis. 1997;175(Suppl 1):S176–82.CrossRefPubMed
9.
Bennett JE, Dolin R, Blaser MJ. Principles and practice of infectious diseases: Elsevier Health Sciences, 8th Edition; 2014.
10.
Organization, W.H. Summary of discussions and recommendations, 16th informal consultation of the global polio laboratory network, 22–23 September 2010. In: WHO/HQ. Geneva: World Health Organization; 2010.
11.
Centers for Disease Control and Prevention (CDC). Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011. MMWR Morb Mortal Wkly Rep. 2011;60(25):846–50.
12.
Center for disease control and prevention (CDC). Update on Vaccine-Derived Polioviruses --- Worldwide, January 2008--June 2009 September 18. 2009;58(36):1002–1006.
13.
Organization, W.H. Global Polio Eradication Initiative: Polio Eradication and Endgame Strategic Plan (2013–2018). Geneva: Report No, WHO/POLIO/13.02; 2013.
14.
Gumede N, Muthambi V, Schoub BD. Immunodeficiency-associated vaccine-derived poliovirus type 3 in infant, South Africa, 2011. Emerg Infect Dis. 2012;18(6):992–4.CrossRefPubMedPubMedCentral
15.
Kim JH, Rho SH. Transmission dynamics of oral polio vaccine viruses and vaccine-derived polioviruses on networks. J Theor Biol. 2015;364:266–74.CrossRefPubMed
16.
17.
Troy SB, et al. Community circulation patterns of oral polio vaccine serotypes 1, 2, and 3 after Mexican national immunization weeks. J Infect Dis. 2014;209(11):1693–9.CrossRefPubMed
18.
Garon JR, Cochi SL, Orenstein WA. The challenge of global poliomyelitis eradication. Infect Dis Clin N Am. 2015;29(4):651–65.CrossRef
19.
Center for Disease Control and Prevention (CDC). Update on vaccine-derived polioviruses--worldwide, January 2006-August 2007. MMWR. 2007;56(38):996–1001.
20.
Center for Disease Control and Prevention (CDC). Update on vaccine-derived polioviruses--worldwide, April 2011-June 2012. MMWR Morb Mortal Wkly Rep. 2012;61:741.
21.
Diop OM, et al. Update on vaccine-derived polioviruses-worldwide, January 2014-march 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):640–6.PubMedPubMedCentral
22.
Buttinelli G, et al. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J Gen Virol. 2003;84(Pt 5):1215–21.CrossRefPubMed
23.
World Health Organisation, Polio Laboratory Manual, 4th Edition; 2004.
24.
Kilpatrick DR, et al. Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR. J Virol Methods. 2014;197:25–8.CrossRefPubMed
25.
Kilpatrick DR, et al. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J Clin Microbiol. 2009;47(6):1939–41.CrossRefPubMedPubMedCentral
26.
Taniuchi M, et al. Kinetics of poliovirus shedding following oral vaccination as measured by quantitative reverse transcription-PCR versus culture. J Clin Microbiol. 2015;53(1):206–11.CrossRefPubMed
27.
28.
Kilpatrick DR, et al. Poliovirus serotype-specific VP1 sequencing primers. J Virol Methods. 2011;174(1–2):128–30.CrossRefPubMed
29.
30.
31.
Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870–4.CrossRefPubMed
32.
33.
Diop OM, et al. Update on vaccine-derived polioviruses-worldwide, July 2012-December 2013. MMWR Morb Mortal Wkly Rep. 2014;63(11):242–8.PubMedPubMedCentral
34.
Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries. Rev Infect Dis. 1991;13(5):926–39.CrossRefPubMed
35.
Hampton LM. Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine-worldwide, 2013-2016. MMWR-Morbidity mortality weekly report. 2015;64(25):699–702.
36.
Garon J, et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016;15(6):693–708.CrossRefPubMed
37.
Al-Hello H, et al. Highly divergent type 2 and 3 vaccine-derived polioviruses isolated from sewage in Tallinn, Estonia. J Virol. 2013;87(23):13076–80.CrossRefPubMedPubMedCentral
38.
Shahmahmoodi S, et al. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia. Virus Res. 2008;137(1):168–72.CrossRefPubMed
39.
Famulare M, et al. Sabin vaccine reversion in the field: a comprehensive analysis of Sabin-like poliovirus isolates in Nigeria. J Virol. 2016;90(1):317–31.CrossRefPubMed
40.
Wahjuhono G, et al. Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: summary of coverage, immunity, and environmental surveillance. J Infect Dis. 2014;210(suppl_1):S347–52.CrossRefPubMed
41.
Tao Z, et al. Isolation and characterization of a type 2 vaccine-derived poliovirus from environmental surveillance in China, 2012. PLoS One. 2013;8(12):e83975.CrossRefPubMedPubMedCentral
Metadata
Title
The detection of 3 ambiguous type 2 vaccine-derived polioviruses (VDPV2s) in Uganda
Authors
Mary Bridget Nanteza
Barnabas Bakamutumaho
Annet Kisakye
Prossy Namuwulya
Henry Bukenya
Edson Katushabe
Josephine Bwogi
Charles Rutebarika Byabamazima
Raffaella Williams
Nicksy Gumede
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2018
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-018-0990-y

Other articles of this Issue 1/2018

Virology Journal 1/2018 Go to the issue

Research

Prevalence and sequence analysis of equid herpesviruses from the respiratory tract of Polish horses

Research

Diagnostic performance of commercial IgM and IgG enzyme-linked immunoassays (ELISAs) for diagnosis of Zika virus infection

Research

Molecular characterization and phylogenetic analysis of a dengue virus serotype 3 isolated from a Chinese traveler returned from Laos

Research

Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment

Research

Multiple organ involvement in severe fever with thrombocytopenia syndrome: an immunohistochemical finding in a fatal case

Research

Histone acetyl transferase TIP60 inhibits the replication of influenza a virus by activation the TBK1-IRF3 pathway
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits